Page last updated: 2024-08-24
bimakalim and 1,3-dipropyl-8-cyclopentylxanthine
bimakalim has been researched along with 1,3-dipropyl-8-cyclopentylxanthine in 1 studies
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Gross, GJ; Grover, GJ; Mei, DA; Sleph, PG | 1 |
Other Studies
1 other study(ies) available for bimakalim and 1,3-dipropyl-8-cyclopentylxanthine
Article | Year |
---|---|
Adenosine A1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim.
Topics: Animals; Benzopyrans; Cardiotonic Agents; Coronary Circulation; Dihydropyridines; Dogs; Heart Rate; In Vitro Techniques; Ion Channel Gating; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Phenylisopropyladenosine; Potassium Channels; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Regression Analysis; Ventricular Function, Left; Xanthines | 1997 |